Five Prime Therapeutics, Inc.
(NASDAQ GS: FPRX)
Rigrodsky Law, P.A. is investigating Five Prime Therapeutics, Inc. (“Five Prime”) regarding possible breaches of fiduciary duties and other violations of law related to Five Prime’s agreement to be acquired by Amgen Inc. Under the terms of the agreement, Five Prime’s shareholders will receive $38.00 in cash per share.